Pembrolizumab extends OS in pretreated hepatocellular carcinoma

Pembrolizumab prolonged OS compared with placebo for certain patients with advanced hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.Pembrolizumab (Keytruda, Merck) also extended PFS and induced a higher objective response rate than placebo among Asian patients with advanced HCC previously treated with sorafenib (Nexavar, Bayer) or oxaliplatin chemotherapy, results of the randomized phase 3 KEYNOTE-394 trial showed.Pembrolizumab, an anti-PD-1 antibody, is approved in the United States for treatment of several cancer types.The FDA grantedRead More

Share on facebook
Share on twitter
Share on linkedin